Substitute Conduction

Approved for use through 1964/2002. QMB 0. U.S. Patent and Trademark Office: U.S. DEPARTIENT OF COM-

the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Sheet 1 of 2

pond to a collection of information unless it	displays a vang Owin control number
Application Number	09/7年12年
Filing Date	February 2, 2001
First Named Inventor	Seth AcFoerster et al.
Group Art Unit	8
Examiner Name	
Attorney Docket Number	END-723

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Doce	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
mos		3,945,375	Banko	3/23/76	ALL	
9		3,996,935		Banko	12/14/76	ALL
		4,210,146		Banko	7/1/80	ALL
		4,250,892		Dolhay et al.	2/17/81	ALL
		4,320,761		Haddad	3/23/82	ALL
		4,699,154		Lindgren	10/13/87	ALL
		4,693,237		Hoffman et al.	9/15/87	ALL
		4,832,685		Haines	5/23/89	ALL
		4,935,005		Haines	6/19/90	ALL
		4,944,308		Akerfeldt	7/31/90	ALL
		4,995,877		Ams et al.	2/26/91	ALL
mus		5,217,478		Rexroth	6/8/93	ALL
-			FC	DREIGN PATENT DOCUMENTS		

	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages	
Examiner Initials		Office ³ Number ⁴		KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	or relevant figures appear	T ⁶
			-					ļ
Examiner Signature	1	Suca	P K	auc	Date Conside	(.120	102	<u>. </u>

Signature | Considered | Consid



Approved for use through 1843/2002. SASE 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMR control number.

Under the Paperwork Reduction Act of 1995, no persons are required to res

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Sheet 2 of 2

3	bound to a confection of unformation inness it	displays a valid Vivia control limitoer.		
1	Application Number	09/776,123>		
	Filing Date	February 2, 2001		
	First Named Inventor	Seth A. Foerster et al.		
	Group Art Unit			
	Examiner Name			
	Attorney Docket Number	END-723		

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document				
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
muss		5,275,609		Pingleton et al.	1/4/94	ALL
9		5,280,457		Figueroa et al.	1/18/94	ALL
		5,329,635		Smith	6/14/94	ALL
mo		5,403,276		Schechter et al.	4/4/95	ALL
0						
-						· ·
*		7				

FOREIGN PATENT DOCUMENTS Date of Publication Pages, Columns, Lines, Foreign Patent Document where relevant passages of Cited Document Name of Patentee or Examiner Cite or relevant figures T٥ mm-dd-yyyy Applicant of Cited Document appear Initials KindCode⁵ Office3 Number4 No.1 Examiner Date 20107 Considered Signature

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter

Tonique citation designation number. 2 See attached Kinds of U.S. Patient Documents. 3 Earth Office that is student the document of the work of the temperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patient and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.